Creative Touch Permanent Makeup and Aesthetics

Niacinamide is the most mechanistically broad single active in barrier-focused skincare. It addresses ceramide synthesis directly by upregulating the rate-limiting enzyme serine palmitoyltransferase (SPT), producing measured 4-fold ceramide increases alongside free fatty acid and cholesterol co-production in the same pathway. This makes it categorically different from topical ceramide application: it restores the synthesis capacity, not just the deficit. Beyond the barrier, niacinamide replenishes NAD⁺ in fibroblasts, reduces fibroblast senescence markers, modulates sebum and melanin transfer, and inhibits glycation-related collagen cross-linking. Its evidence base is the deepest of any non-prescription topical active in current clinical use.

Niacinamide – the amide form of vitamin B3 – is the single homecare active with the broadest and most consistently evidenced mechanism in skin biology. Unlike many cosmeceutical ingredients whose mechanisms are extrapolated from marginal in vitro data, niacinamide’s effects on ceramide synthesis, NAD⁺ metabolism, sebum regulation, pigmentation, and fibroblast function are each supported by distinct and replicable research pathways. It is also one of the few topical actives whose primary benefit works at the enzymatic level – addressing a synthesis rate, not simply supplementing a product – which makes its effect more durable than passive ingredient delivery.

Ceramide Synthesis: Mechanism, Not Supplementation

The barrier benefit of niacinamide is categorically different from applying ceramides topically. Topical ceramides replenish a structural deficit in the stratum corneum; niacinamide addresses the synthesis capacity that was producing insufficient ceramides in the first place.

The mechanism is precise. Niacinamide upregulates the transcription of LCB1 and LCB2 – the subunit genes encoding serine palmitoyltransferase (SPT), the rate-limiting enzyme that initiates de novo ceramide synthesis from serine and palmitoyl- CoA. Tanno et al. (2000) demonstrated that cultured normal human keratinocytes treated with 1–30 µmol/L niacinamide for six days increased ceramide biosynthesis dose-dependently by 4.1–5.5-fold, with upregulated SPT activity confirmed at the mRNA level. The effect was not isolated to ceramides: free fatty acid synthesis increased 2.3-fold and cholesterol synthesis increased 1.5-fold in the same concentration range. ^[3]

This lipid triad co-production is clinically significant. The stratum corneum’s lamellar matrix requires ceramides, cholesterol, and free fatty acids in approximately equimolar ratios; a treatment that upregulates ceramide synthesis without the supporting lipids produces a less complete lamellar structure than one that lifts all three together. Niacinamide achieves the co-production through a single enzymatic intervention. Topical application in vivo reduces TEWL in dry skin, consistent with the in vitro synthesis data translating to functional barrier improvement. ^[3]

The SPT upregulation is genomic rather than transient: niacinamide increases LCB1 and LCB2 mRNA expression, meaning the synthesis capacity is restored at the transcriptional level, not bypassed by substrate flooding. That distinction matters in inflamed or cytokine-suppressed skin: where IL-4 and IL-13 are actively suppressing SPT through the STAT6 ceramide synthesis suppression pathway (established in the Ceramides entity), niacinamide’s effect at the transcriptional level may be partially offset by that cytokine suppression. The barrier benefit from niacinamide is most complete when the inflammatory environment has also been addressed.

NAD⁺ and the Dermis Connection

Niacinamide is a direct precursor to NAD⁺ (nicotinamide adenine dinucleotide) and NADP⁺. These cofactors are not simply energy molecules, they participate in redox reactions that maintain mitochondrial function in both keratinocytes and fibroblasts, support DNA repair enzymes ( sirtuins, PARP), and regulate the cellular senescence pathways that accelerate dermal ageing. ^[2]

A 2024 Nature Scientific Reports study evaluated niacinamide’s effect on fibroblast senescence markers directly. Applied in a topical formula, niacinamide downregulated 20 ageing- and SASP-related genes, including MMP-12, MMP-1, and CXCL9, in aged human fibroblasts in vivo, reducing the senescence-associated secretory phenotype that drives ongoing ECM degradation. ^[1] Niacinamide also increased the replicative lifespan and clonogenicity of primary human keratinocytes in culture, enriching for holoclone stem-cell populations, the most regeneratively capable keratinocyte subtype. These dermal and epidermal effects operate through NAD⁺ replenishment rather than the SPT ceramide pathway, making them genuinely independent mechanisms rather than downstream consequences of the same intervention.

The practical implication is that niacinamide’s dermis-level contribution – reduced SASP, reduced MMP secretion, maintained fibroblast viability – is not a secondary benefit to its barrier function. It is a parallel mechanism acting on a different layer. This is not simply a barrier active that also happens to affect collagen; it is a molecule that operates at meaningful depth across the full skin architecture.

Sebum, Pigmentation, and Glycation

Beyond barrier and ECM function, three further mechanisms are relevant to clinical skin presentations.

Sebum regulation: Niacinamide reduces sebum production through a mechanism involving the reservoir in the duct connecting sebaceous glands to the skin surface. The precise pathway is not fully characterised, but the clinical evidence for sebum reduction is consistent across multiple studies. ^[2] This is why niacinamide is effective across both barrier-compromised dry presentations and oily/blemish-prone presentations simultaneously; a mechanistic flexibility that few single actives share.

Melanin transfer inhibition: Niacinamide does not suppress melanin synthesis in melanocytes. Its depigmenting effect operates downstream: it inhibits the transfer of melanosomes from melanocytes to surrounding keratinocytes, reducing the visible accumulation of pigment in the stratum corneum regardless of melanocyte activity. ^[2] For uneven skin tone and post-inflammatory hyperpigmentation, this is a genuinely distinct mechanism from tyrosinase-inhibiting actives such as hydroquinone or kojic acid.

Glycation inhibition: Niacinamide has demonstrated anti-glycation activity, reducing the formation of advanced glycation end products (AGEs) in dermal collagen – the cross-linking reaction between collagen proteins and glucose derivatives that produces skin yellowing and structural stiffening. ^[2] This connects directly to the Glycation entity and provides a homecare contribution to the AGE-driven collagen rigidity that professional treatments cannot fully address between sessions.

Concentration and Formulation

The SPT upregulation and lipid synthesis benefits occur at concentrations as low as 1–30 µmol/L in vitro, equivalent to the 2–5% concentrations found in most established topical formulations. The concern about niacinamide causing flushing (prostaglandin D2-mediated vasodilation) is a class effect of nicotinic acid, a different vitamin B3 form, not niacinamide. At 2–5% topical concentration, flushing is not a meaningful clinical concern. Formulations above 5% offer diminishing marginal returns on barrier synthesis effects without proportional additional benefit, and can cause mild transient irritation in reactive skin. Niacinamide is stable across a wide pH range and compatible with most actives including retinoids, AHAs, and vitamin C; a genuine formulation advantage for multi-active routines.